Hilton Boston Logan Airport, One Hotel Drive,

Boston,

MA,

US,

ZIP: 02128

Phone: (+1) 617 455 4188

The incidence of wet-AMD and diabetic eye diseases are increasing globally. Current treatment options place a significant treatment burden on patients, but a flourishing pipeline of innovative therapeutic options with high efficacy and lower invasiveness is disrupting the status quo.

The Retinal Vascular Disease Drug Development Summit will unite the industry leaders at the forefront of developing and delivering these innovative treatments, providing you with an unparalleled quality of technical insights specifically enabling you to progress your retinal vascular disease pipeline more quickly and effectively to get these innovative therapeutics to market.

Tickets    https://go.evvnt.com/1373480-1?pid=1052
Brochure https://go.evvnt.com/1373480-3?pid=1052

Prices:
Conference + 2 Workshops USD 4097.00
Conference + 1 Workshop USD 3498.00
Conference Only USD 2899.00

Category: Conferences | Science, Health & Medicine | Pharmaceuticals

Arun Upadhyay, Ocugen, Ruchi Sharma, National Eye Institute, Kalliopi Stasi, Tenpoint Therapeutics, Abraham Scaria, AGTC, Kip Connor, Biogen, Stephen Poor, Novartis AG, David Silverman, Roche, David Lally, New England Retina Associates, Simon Kaja, Experimentica Ltd, Daniel Chao, Janssen Global Services, LLC, Michael Stewart, Mayo Clinic, David Tanzer, Occuterra Therapeutics, Raj Singh Thakur, Queen's University Belfast, Moshe Weinstein, Everads-Therapy, Thomas Ciulla, Clearside Biomedical, Joel Naor, Opthea Limited, Brian Levy, Inflammx Therapeutics, Michael Miller, Glycadia Inc., Alan Franklin, ForwardVue Pharma, Ivo Stoilov, Genentech Inc